Owing to its irritant-sensing properties, TRPA1 has gained considerable interest as a pharmacological target in diseased conditions to control symptoms such as pain, itch, cough, or neurogenic inflammation, including migraine. This evidence concerns the gene TRPA1 and migraine disorder.